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Analyses describing outcomes of kidney transplantation
usually exclude the survival of wait-listed patients and
dialysis patients with failed kidney transplants, and thus
reflect only a portion of the typical transplant process.
We determined death rates during the continuum of
wait-listing, transplantation, and after allograft failure among
adult end-stage renal disease patients in the United States
between 1995 and 2003. Before transplantation, death rates
increased with longer waiting times. Death rates were lowest
during the period of allograft function and highest after
allograft failure. Patients were at particularly high risk during
periods of transition between dialysis and transplantation
(death rates during the peri-transplant period and during the
re-initiation of dialysis after transplant failure were 8.2/
100 patient-years (95% confidence interval (CI) 7.7, 8.8) and
17.9/100 patient-years (95% CI 15.7, 20.3), respectively
compared to 6.4/100 patient-years (95% CI 6.25, 6.51) during
the period of wait-listing. Diabetic patients and older patients
were at increased risk at all time points. The most common
known cause of death in all age subgroups was
cardiovascular disease. The proportion of death owing to
sepsis was greatest after allograft failure (16.8% of all deaths
were due to sepsis compared to 14.0% during wait-listing,
and 12.7% during the period of allograft function).
Consideration of the entire transplant experience as a whole
should help to focus patient care on periods of particularly
high risk, and emphasizes opportunities to improve
outcomes by strategies aimed at preventing death owing to
cardiovascular and infectious causes.
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The traditionally reported clinical outcomes in kidney
transplant recipients include graft failure and death with
graft function. However, because end stage renal disease
patients are now wait-listed for prolonged periods before
deceased donor transplantation,1 and because more patients
are returning to dialysis after allograft failure,2 focusing solely
on outcomes related to graft function captures only a portion
of the transplant experience for most patients. These factors
suggest that consideration of the risks and benefits of kidney
transplantation should also include clinical events in the
wait-listed and transplant failure populations. In this study,
we describe mortality rates during the continuum of renal
replacement therapy from the period of wait-listing before
transplantation, during the period of allograft function, and
finally during the return to dialysis after allograft failure. We
specifically focus on the transitions between dialysis and
transplantation as high risk periods for patient mortality.
A secondary objective was to describe causes of death during
high risk periods, which may help to identify strategies that
will improve outcomes. Examination of death rates during
the continuum of wait-listing, transplantation, and after
allograft failure should lead to development of strategies to
improve patient care during periods of increased risk.
RESULTS
The majority of patients wereo50 years of age, male, and of
white race (Table 1). Diabetes was the cause of end-stage
renal disease in 36% of patients, more patients were wait-
listed in recent years, and most patients were activated to the
waiting list within 1 year after starting dialysis. Table 2 shows
patient characteristics at the beginning of each of the
different time periods (wait-listing, allograft function, and
after allograft failure). It is important to recognize that
patients included in the analyses of death rates during the
period of allograft function were the subset of the wait-listed
patients who received a transplant. Similarly, patients
included in the analyses of death rates after allograft failure
were the subset of transplant recipients who suffered allograft
failure.
Figure 1 shows unadjusted death rates from all causes
among diabetic and nondiabetic study patients. Death rates
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increased progressively during the period of wait-listing and
increased more rapidly among diabetic patients. Death rates
were elevated during the peri-transplant period and then
stabilized after the first post-transplant year. During the
period of allograft function, death rates were higher in
patients with longer dialysis exposure (i.e., death rate in
patients with dialysis exposureo3 years was 3.1/100 patient-
years, 95% CI 2.9–3.2, whereas the death rate in patients with
dialysis exposure X3 years was 4.3/100 patient-years, 95%
CI 4.0–4.6). Death rates were highest during the transition
back to dialysis after allograft failure (17.9/100 patient-years
(95% CI 15.7–20.3)). We found no association between
the duration of allograft function before transplant failure
and death during the transition back to dialysis (P¼ 0.64).
We specifically tested the hypothesis that patients who
suffered early graft loss (graft survival o3 months) may
be at increased risk of mortality, but found no differences
in the overall or cause-specific death rates in this subgroup.
During the first 2 years after the transition back to dialysis
after allograft failure, 18.4% of patients died on dialysis,
whereas 12.2% received repeat transplants. Among patients
with allograft failure, death rates peaked at 3 months after
allograft failure before declining. Overall death rates after
allograft failure were slightly higher in patients treated with
hemodialysis (10.7/100 patient-years, 95% CI 9.7–11.6)
compared to peritoneal dialysis (7.9/100 patient-years, 95%
CI 5.4–10.4).
The death rates during the period of wait-listing in
Figure 1 were determined excluding patients who were
removed from the transplant waiting list, whereas death rates
during the transition from dialysis to transplantation and
during the period of allograft function included both
deceased donor transplant recipients and wait-listed patients
who received living donor transplants. Table 3 shows that
death rates were higher when patients removed from
the waiting list were included in the analysis. Death rates
during the transition from dialysis to transplantation and
during the period of allograft function were higher in
deceased compared to living donor transplant recipients
(Table 3).
Figure 2 shows the death rates among patients of different
age at the beginning of each time period (wait-listing,
allograft function, and after allograft failure). Older patients
had markedly higher death rates throughout all of the time
periods of observation, and the death rate in patients 460
years of age was markedly increased during the transitions
between dialysis and transplantation. Figure 3 shows cause-
specific death rates in diabetic (left panel) and nondiabetic
(right panel) patients. Cardiovascular deaths were the most
common known cause of death during all time periods.
Deaths owing to sepsis were relatively increased in the first
three months after allograft failure (16.8% of all deaths were
due to sepsis compared with 14.0% during wait-listing, and
12.7% during the period of allograft function). A significant
proportion of deaths were owing to unknown causes (14, 52,
and 21% of all deaths during the period of wait-listing,
allograft function, and after allograft failure, respectively).
Death rates (per 100 patient-years) due to cancer (included
under the category of other in Figure 3) were 0.18 (95% CI
0.16–0.20) during wait-listing, 0.11 (95% CI 0.09–0.13)
during allograft function, and 0.25 (95% CI 0.16–0.39) after
allograft failure.
DISCUSSION
The novelty of this study lies in its consideration of the
transplant experience as an integrated whole, rather than
focusing on individual components, which do not reflect the
usual experience of most patients. Instead, we describe death
rates during the usual progression of patients through the
transplant experience from wait-listing to transplantation,
and back to dialysis after transplant failure. Death rates
increased in a linear fashion during the wait-list period, were
lowest during the period of allograft function, and were
highest after allograft failure. The transitions between dialysis
and transplantation were identified as high risk periods for
mortality, especially for diabetic patients and older patients,
who had markedly increased risks of death during these
periods in addition to their higher baseline risk of death.
Table 1 | Study patient characteristics (n=89 202)
Characteristic Percentage
Patient age (years)a
18–39 24.2
40–49 23.7
50–59 28.6
X60 23.5
Male gender 60.1
Race
White 59.5
Black 31.9
Other 8.6
Cause of end-stage renal disease
Glomerular disease 24.7
Diabetes 35.7
Other 39.6
Hemodialysis as first treatment modality 83.5
Year of placement on waiting list
1995 1.7
1996 7.1
1997 9.9
1998 11.5
1999 12.7
2000 13.7
2001 13.9
2002 14.5
2003 15.1
Duration of dialysis before placement on waiting list (months)
o12 56.5
12–23 26.7
X24 16.8
aAt time of first treatment for end-stage renal disease.
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Identifying high risk periods during the usual transplant
experience should help to focus patient care and may
ultimately lead to improved patient outcomes.
Period of wait-listing for kidney transplantation
Our findings demonstrate the impact of increased waiting
time for transplantation. Death rates increased with increased
waiting time and were higher when patients removed from
the waiting list were included in the analysis. Including
deaths that occur after removal from the transplant waiting
list provides a more complete assessment of the consequences
of increased waiting times for transplantation.
The leading known cause of death during the period of
wait-listing was cardiovascular disease (CVD), and the CVD-
specific death rates we report are similar to those documented
in other studies.3 The importance of CVD in the wait-listed
dialysis population has been highlighted in a number of
publications.3–5 Indeed, as waiting times continue to increase,
death on the waiting list will be a frequent end point for
transplant candidates in certain patient subgroups (i.e., the
elderly and diabetic patients). For example, our analyses
show that a nondiabetic male patient aged 60 years activated
Table 2 | Characteristics of patients included in each time perioda
Wait-listing Allograft function After allograft failure P-value
Number of patients 89 202 47 433 5461
Age (mean and s.d.) 49.6 (13.0) 49.2 (13.2) 47.9 (13.5)
Percent male 60.1 61.7 60.7 o0.0001
Race
White 59.5 65.9 57.6 o0.0001
Black 31.9 27.1 37.9
Other 8.6 7.0 4.5
Cause of end-stage renal disease
Glomerular 24.7 29.3 32.0 o0.0001
Diabetes 35.7 29.7 25.1
Other 39.6 41.0 42.9
Year of placement on the waiting list
1995–1999 42.1 54.5 74.9 o0.0001
2000–2001 27.6 27.2 18.9
2002–2003 29.6 18.3 6.3
Duration of dialysis before placement on waiting list (months)
o12 56.5 63.3 65.9 o0.0001
12–23 26.7 24.3 23.5
X24 16.8 12.4 10.6
Duration of dialysis before transplantation
(median, and 25th and 75th percentile)
N/A 380 (157 785) 318 (131 683)
Duration of allograft survival
(median, and 25th and 75th percentile)
N/A N/A 546 (97 1145)
Deaths N (%)
Overall 10 836 (12.2) 4927 (10.4) 1474 (27.0)
Sepsis 1562 (14.4) 539 (10.9) 230 (15.6)
CHF 4891 (45.1) 788 (16.0) 553 (37.5)
Other 2868 (26.5) 887 (18.0) 390 (26.5)
Unknown 1515 (14.0) 2713 (55.1) 301 (20.4)
aCharacteristics were determined at the beginning of each time period.
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Figure 1 | Unadjusted death rates (per 100 patient-years)
in diabetic and nondiabetic patients. Death rates per 100
patient-years were determined in serial Poisson models in 3-month
intervals during periods of wait-listing, allograft function, and after
allograft failure. Death rates were determined in 2-week intervals for
a period of 3 months during the transition from dialysis to
transplantation (peri-transplant period) and during the transition
back to dialysis after allograft failure. The X-axis denotes time in years
during three distinct time periods—wait-listing, transplantation, and
after transplant failure.
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to the transplant waiting list with an expected waiting time of
5 years has a 43% chance of dying before transplantation.
This finding supports recent recommendations regarding the
optimal use of expanded criteria donor (ECD) kidneys.6
Although the outcomes after ECD kidney transplantation are
clearly inferior to those with ideal donor kidneys, ECD
kidneys continue to provide a survival benefit in patient
groups with high mortality rates on dialysis (i.e., older
patients and patients with diabetes).
In this study, the death rate in the first 90 days after
permanent removal from the transplant waiting list was 34.0/
100 patient-years (95% CI 31.1, 37.1), reinforcing the
potential to improve health by preventing complications in
wait-listed patients. Although increasing the number of
transplant recipients using ECD and other novel strategies
remains an important policy objective, our findings highlight
the need for development of optimal strategies to prevent,
detect, and treat CVD in the wait-listed population.
Peri-transplantation period
Among transplant recipients, death rates were highest during
the peri-transplant period and during the return to dialysis
after allograft failure. The increased risk of death during the
peri-transplant period was highlighted by Wolfe et al.7 is
primarily due to CVD. Transplantation is unique because it
represents an elective surgical procedure performed under
emergent conditions in a high risk population and thus the
relatively high peri-operative risk may be difficult to
eliminate. Adoption of a predictable organ allocation strategy
that permits medical reassessment of wait-listed patients
close to the time of transplantation is one potential strategy
to reduce peri-transplant mortality. Adoption of prophylactic
measures known to be beneficial in other high risk surgical
patients may also be beneficial in patients undergoing
transplantation.8,9
Period with a functioning allograft
After successfully completing the peri-transplant period,
patients with a functioning allograft had relatively low death
rates that did not increase during the time period of
Table 3 | Death ratesa including patients removed from the waiting list, and living and deceased donor transplant recipients
Death rate in wait-listed patients
Death rate during transition from dialysis
to transplantation (0–3 months
post-transplantation)
Death rate during the
period of allograft function
Only wait-listed patients (patients censored at time of
removal from waiting list)
Deceased and living donora
transplant recipients
Deceased and living donora
transplant recipients
6.38 (6.25–6.51) 8.18 (7.65–8.75) 2.65 (2.55–2.76)
Including deaths within 90 days of removal from
waiting list
Deceased donor recipients only Deceased donor recipients only
6.71 (6.58–6.84) 9.57 (8.90–10.30) 3.06 (2.93–3.20)
Including all deaths in patients removed from
waiting list
Living donor recipientsa only Living donora recipients only
7.02 (6.89–7.16) 4.48 (3.77–5.33) 1.59 (1.45–1.75)
Death rates per 100 patient-years and 95% confidence intervals are shown.
aPatients were wait-listed for deceased donor transplantation but received living donor transplants.
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Figure 2 | Death rates in different patient age groups. Age was
determined at the beginning of each time period (wait listing,
transplantation, and after allograft failure). The X-axis denotes time in
years during three distinct time periods—wait-listing, transplantation,
and after transplant failure.
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Figure 3 | Cause-specific death rates in diabetic (left panel) and
nondiabetic (right panel) patients. The X-axis denotes time in years
during three distinct time periods—wait-listing, transplantation, and
after transplant failure.
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observation (3 years). Consistent with other studies, we
found that the death rates were higher in patients with longer
durations of dialysis exposure before transplantation.10,11 The
relatively low death rates in patients with allograft function
should be interpreted with the knowledge that death rates in
transplant recipients are far higher than those among age-
matched individuals in the general population.2,12 Thus, the
provision of allograft function alone is insufficient, and
ongoing health promotion including CVD risk reduction and
cancer surveillance should continue to be emphasized in
transplant recipients according to published guidelines.13,14
As with the wait-listed population, development of optimal
strategies for CVD disease surveillance is clearly needed for
transplant recipients.
Period after allograft failure and return to dialysis
The high death rate among patients who return to dialysis
after allograft failure is an area of considerable concern that
has been highlighted in a number of recent publications.15–18
The number of patients who return to dialysis after
transplant failure is increasing.2 Approximately 50% of failed
kidney transplant recipients will die on dialysis and this
proportion has not been changed since 1996.2 CVD remained
the most important cause of death, but deaths owing to
sepsis were more common during this period than during
any other interval. These trends were consistent in all age
subgroups and among diabetic and nondiabetic patients.
Judicious tapering of immunosuppression after transplanta-
tion and timely creation of arteriovenous vascular access may
help to reduce deaths attributable to sepsis after transplant
failure. The role of nephrectomy in the management of
transplant failure patients remains uncertain but may be pre-
ferable to continued immunosuppression in some transplant
failure patients. We also found that the duration of allograft
survival was not associated with survival after transplant
failure. This is consistent with the results of previous work
demonstrating that the total duration of end-stage renal
disease (waiting time plus duration of allograft survival) was
not associated with survival after allograft failure.16
We previously reported that immunologic and transplant-
related factors including the use of induction agents, acute
rejection, donor source, and the highest glomerular filtration
rate attained during the period of allograft function were not
associated with patient survival after allograft failure.16
However, factors possibly related to chronic kidney disease
care including the serum albumin level at the time of
transplant failure were associated with survival after trans-
plant failure. In this study, we also reported that patients who
returned to dialysis after allograft failure with a higher level of
residual renal function were at increased risk of death,
suggesting that this was a marker for disease severity with the
sickest patients requiring dialysis at higher levels of residual
allograft function.
This study has some limitations to consider, including its
retrospective and administrative data source. Although it is
unlikely that deaths were missed (because mortality must be
reported to the Social Security Administration by statute),
the cause of death was missing or unknown in 23.7% of cases,
and therefore our findings regarding cause-specific mortality
should be interpreted with caution.19 It is possible that some
patients who returned to dialysis with transplant failure
actually lost allograft function because they were in the
process of dying from other causes (e.g., severe heart failure).
However, the fact that death rates did not peak until 3
months after the return to dialysis, and the fact that patients
with short and long durations of graft function had similar
death rates after transplant failure suggests that this
possibility is less likely.
In summary, we describe death rates during the usual
progression of patients through the transplant experience. By
presenting death rates during the continuum of renal
replacement therapy from wait-listing to transplantation
and after transplant failure, we identify periods of increased
risk. Although none of our individual findings are novel
when considered alone, presenting death rates as a con-
tinuum should help to focus patient care and may ultimately
lead to improved outcomes. Our findings indirectly suggest
that fragmentation of patient care during the transition
between transplantation and dialysis is a significant issue.
Therapeutic strategies to enhance patient care during
transitions between dialysis and transplantation should be
prioritized.
MATERIALS AND METHODS
We used the standard analysis files of the United States Renal Data
System to perform this study. We studied adult patients (418
years), who began dialysis treatment between April 1995 and
December 2003 and who were subsequently activated to the kidney
only transplant waiting list. All study patients had a new Health
Care Financing Administration (HCFA) 2728 form available for
analysis. We excluded patients activated to the transplant waiting list
before initiation of chronic dialysis treatment, patients listed for
combined organ transplantation, and preemptive kidney transplant
recipients. Patient characteristics were described using frequencies
or the mean and standard deviation as appropriate. Serial Poisson
regression models were used to determine death rates per 100
patient-years. Overall and cause-specific death rates were deter-
mined. Death and cause of death were determined from the Death
Notification Form (HCFA 2746). Deaths were classified as
cardiovascular, septic, other (with no single cause of death 46%
of all deaths), and unknown. Death rates were determined in
3-month intervals during the periods of wait-listing, allograft
function, and after allograft failure. For example, the death rate
during the first 3 months after activation to the waiting list was
determined in all n¼ 89 202 study patients. The death rate between
the third and sixth month on the waiting list was determined among
(n¼ 88 308) the patients who survived the initial 3-month period
on the waiting list and remained active on the transplant waiting list.
Death rates during transitions between dialysis and transplantation
were determined in 2-week intervals for a period of 3 months.
During the period of wait-listing, death rates were determined with
and without patients who were permanently removed from the
waiting list, but included patients who were temporarily inactive on
the waiting list. During the transition from dialysis to transplantation,
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and the period of allograft function, death rates were determined
with and without patients who were wait-listed for deceased donor
transplantation but received a living donor transplant. After
allograft failure, death rates were determined among patients who
remained on dialysis and excluded repeat transplant recipients.
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